Aim: To evaluate adult height (AH) among girls with central precocious puberty (CPP) treated with gonadotropin releasing hormone analog (GnRHa) and to assess the impact of post-treatment growth on AH. Study design: Medical records of girls with CPP were reviewed. Results: Twenty-six girls aged 7.2 ± 2.0 years were identified. There was a significant difference between AH and predicted adult height (PAH) at the initiation of therapy (p = 0.005). Using univariate analysis, the only factor associated with AH was total growth after discontinuation of therapy. Growth after discontinuation of therapy was variable and often greater than expected. Both age and skeletal age at the end of therapy had strong linear relationships with growth after therapy explaining 60% of this growth. Conclusion: This report confirms that AH is normal among females with CPP treated in a timely fashion with GnRHa. The lack of pre-dictability of growth after discontinuation of therapy suggests that the decision to stop treat-ment should be individualized.
- Central precocious puberty
- Final adult height
- GnRa therapy
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Pediatrics, Perinatology, and Child Health